Vopratelimab

DRUG3 trials

Sponsors

Jounce Therapeutics, Inc.

Conditions

CancerNSCLC

Phase 1

Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors

TerminatedNCT04319224

Jounce Therapeutics, Inc.Cancer

Start: 2020-03-10End: 2023-01-03Updated: 2024-05-30

Phase 2

Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer

CompletedNCT03989362

Jounce Therapeutics, Inc.Cancer

Start: 2019-06-06End: 2022-03-15Updated: 2022-09-10

Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen

TerminatedNCT04549025

Jounce Therapeutics, Inc.NSCLC

Start: 2020-10-19End: 2024-04-25Updated: 2024-05-22

Related Papers

Phase 2 study of PD-1 inhibitor JTX-4014 alone and in combination with vopratelimab, an ICOS agonist, in biomarker-selected subjects with metastatic NSCLC after one prior platinum-containing regimen (SELECT).

Journal of Clinical Oncology2021-05-206 citations

Abstract 5536: ICOS hi CD4 T cells emerging on vopratelimab treatment have Th1 central memory characteristics and may contribute to durability of clinical responses

Cancer Research2020-08-151 citations